![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
AVTE Aerovate
- 2.450
- -0.010-0.41%
Close Feb 14 16:00 ET
- 2.450
- 0.0000.00%
Post 16:01 ET
71.01MMarket Cap-0.82P/E (TTM)
2.500High2.430Low114.17KVolume2.490Open2.460Pre Close279.96KTurnover0.95%Turnover RatioLossP/E (Static)28.99MShares32.41552wk High0.88P/B29.31MFloat Cap1.25052wk Low--Dividend TTM11.96MShs Float32.415Historical High--Div YieldTTM2.85%Amplitude1.250Historical Low2.452Avg Price1Lot Size
Aerovate Stock Forum
Sign in to post a comment
$Aerovate (AVTE.US)$ thanks in 2,40 out 2,89
2
4
$Aerovate (AVTE.US)$ good volume kick in
$Aerovate (AVTE.US)$ seems not good to me
$Aerovate (AVTE.US)$ not moving yet
1
$Aerovate (AVTE.US)$ Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
$Aerovate (AVTE.US)$
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
1
No comment yet
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025
103892611 : yes
WeiTheSaint469 OP : thank God I got out lol